1.
Differential microRNAs expression in acute graft-versus-host disease as potential diagnostic biomarkers
Motaei, J., Yaghmaie, M., Pashaiefar, H., Mousavi, S. A., Ghavamzadeh, A., Ahmadvand, M., Kerachian, M. A.
Bone marrow transplantation. 2020
2.
FLT3-ITD compared with DNMT3A R882 mutation is a more powerful independent inferior prognostic factor in adult AML patients after Allogeneic Hematopoietic Stem Cell Transplantation: A retrospective cohort study
Ardestani, M. T., Kazemi, A., Chahardouli, B., Mohammadi, S., Nikbakht, M., Rostami, S., Jalili, M., Vaezi, M., Alimoghaddam, K., Ghavamzadeh, A.
Turkish journal of haematology : official journal of Turkish Society of Haematology. 2018
Abstract
OBJECTIVE To identify DNMT3A exon 23 mutations and their prognostic impact in the presence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients treated with Allo-HSCT. MATERIALS AND METHODS This study analyzed128 adult AML patients referred to the Hematology-Oncology & Stem Cell Research Center of Shariati hospital. FLT3-ITD and NPM1 mutations were detected using fragment analysis. For DNMT3A exon 23 mutation analysis, we used Sanger sequencing. Survival curves were estimated by the Kaplan-Meier method and the differences between groups were compared using Log-Rank test. RESULTS The incidence of DNMT3A exon 23 mutations was 15.6% and the hotspot region R882 mutations were prominent. Overall survival (OS) and Relapse-free survival (RFS) were compared in patients with and without DNMT3A exon 23 mutations using univariate analysis and there was no significant difference between two groups of patients. On the contrary, the FLT3-ITD mutation significantly reduced the OS (p=0.009) and RFS (p=0.006) rates in AML patients after allogeneic hematopoietic cell transplantation (Allo-HSCT). In the next step, AML patients were divided into four groups according to DNMT3A and FLT3-ITD mutations. Patients with DNMT3A R882mut/FLT3-ITDpos had the worst OS and RFS. These results indicate that DNMT3A mutations alone cannot affect the clinical outcomes of AML patients treated with Allo-HSCT, but when accompanied by FLT3-ITD mutations, the overall survival was significantly reduced (5-year OS 0% for DNMT3AR882mut/FLT3-ITDpos patients vs 62% DNMT3AR882wt/FLT3-ITDneg, p=0.025) and relapse incidence rate increased. CONCLUSION It can be deduced that DNT3A R882mut/ FLT3-ITDpos is a poor prognostic factor in AML patients even after Allo-HSCT.
3.
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
Ringden, O., Labopin, M., Sadeghi, B., Mailhol, A., Beelen, D., Floisand, Y., Ghavamzadeh, A., Finke, J., Ehninger, G., Volin, L., et al
Journal of Internal Medicine. 2017
Abstract
BACKGROUND Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic haematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve for severe aGVHD. OBJECTIVES We wanted to analyze the long-term outcome in patients who survive severe aGVHD. METHODS This study was a landmark analysis of 23 567 patients with acute Leukaemia who survived for more than 6 months after HSCT, 2002-2014. Patients alive after severe aGVHD (n = 1738) were compared to controls. RESULTS Patients with severe aGVHD had higher non-relapse mortality (NRM) and higher rate of extensive chronic GVHD (cGVHD) than the controls (P < 10-5 ). The probability of relapse was significantly lower in the severe aGVHD group, but Leukaemia-free survival (LFS) and overall survival were significantly lower than for the controls (P < 10-5 ). Five-year LFS in patients with severe aGVHD was 49%, as opposed to 61% in controls with no or mild GVHD and 59% in patients with moderate GVHD. CONCLUSIONS HSCT patients who survive severe aGVHD have higher risk of developing extensive cGVHD, a higher NRM, a lower relapse probability, and lower LFS than other HSCT patients. This study is a platform for outcome analysis in patients treated with novel therapies for acute GVHD. Copyright © 2017 The Association for the Publication of the Journal of Internal Medicine.
4.
The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation
Mousavi, S. A., Javadimoghadam, M., Ghavamzadeh, A., Alimoghaddam, K., Sayarifard, A., Ghaffari, S. H., Chahardouli, B., Basi, A.
International Journal of Hematology Oncology & Stem Cell Research. 2017;11(1):24-29
Abstract
Background: The study attempts to assess the relationship between chimerism analysis using polymerase chain reaction of short tandem repeat (STR) and the incidence of chronic graft versus host disease (GvHD) as well as survival. Subjects and Methods: The retrospective cohort included all patients who received allo-HSCT during 2005-2013. Data collected by day +100 were reviewed in terms of the incidence of chronic GvHD and survival. Chimerism was evaluated for whole blood, T-cell and PMN cells on days 15, 30 and 60, respectively using polymerase chain reaction of short tandem repeat (STR). Results: Forty (69%) patients developed chronic GvHD, 11 (19%) relapsed and 22 (39.7%) expired during the study. There was a significant relationship between chronic GvHD and chimerism analysis including whole blood on day 60 (p=0.001), Polymorphonuclear neutrophil (PMN) on day 60 (p=0.05), T-cell on days 15 (p=0.028), 30 (p=0.01) and 60 (p=0.004). Patients with chronic GvHD showed a long-term survival as compared with those without chronic GvHD (p=0.0013). Conclusion: Conducting continuous analysis of chimerism provides an opportunity to initiate immediate measures in order to prevent complications.